发明名称 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
摘要 The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
申请公布号 US8999324(B2) 申请公布日期 2015.04.07
申请号 US201113196724 申请日期 2011.08.02
申请人 Roche GlycArt AG 发明人 Umaña Pablo;Jean-Mairet Joël;Bailey James E.
分类号 A61K39/395;C12P21/08;C12N9/10;C07K16/00;C07K16/28;C07K16/30;C12P21/00;A61K39/00 主分类号 A61K39/395
代理机构 Sterne, Kessler, Goldstein & Fox PLLC 代理人 Sterne, Kessler, Goldstein & Fox PLLC
主权项 1. A method of treating cancer in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a composition comprising a recombinant antigen binding molecule comprising an immunoglobulin Fc region containing variant glycoforms, wherein said antigen binding molecule is obtained from a Chinese Hamster Ovary cell that has been genetically manipulated to have altered glycosyltransferase expression, and wherein said antigen binding molecule has increased Fe-mediated cellular cytotoxicity compared to the corresponding antigen binding molecule lacking the variant glycoforms obtained from a Chinese Hamster Ovary cell that does not have altered glycosyltransferase expression.
地址 Switzerland DE